Editorial Commentary: Amniotic Orthopaedic Biologics: There's Hope If We Avoid Hype

Area of Science:

• Regenerative Medicine
• Biologics
• Tissue Engineering

Background:

• Amniotic products, historically used for wound care, are being explored for inflammatory diseases like osteoarthritis and tendinopathies.
• These products are classified as human cells, tissues, or cellular or tissue-based products (HCTPs) under the FDA's
• 351
• category, requiring biologic license approval.
• Current clinical use for these indications is pending rigorous safety and efficacy trials.

Discussion:

• Basic science and clinical studies are accumulating evidence for the therapeutic potential of amniotic products.
• The anti-inflammatory, anticatabolic, and proanabolic properties of proteins within these allografts are key to their proposed mechanism of action.
• Regulatory caution from the FDA should not deter continued investigation into these promising regenerative therapies.

Key Insights:

• Amniotic suspension allografts have demonstrated safety and a lack of significant immune response in animal and human studies.
• Prospective and randomized controlled trials suggest efficacy in treating knee osteoarthritis compared to hyaluronic acid and placebo.
• The inherent biological properties of amniotic allografts support their potential in treating degenerative and inflammatory joint conditions.

Outlook:

• Further research is crucial to fully elucidate the therapeutic applications of amniotic products in regenerative medicine.
• Successful navigation of the FDA's regulatory pathway for HCTPs is essential for future clinical accessibility.
• Continued investigation holds the potential to expand the use of amniotic-derived therapies for a range of inflammatory and degenerative diseases.